StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)

Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –

Kiniksa Pharmaceuticals International operating margin

Operating margin is operating income as a percentage of revenue.

Kiniksa Pharmaceuticals International's operating margin for the twelve months ending Sep 30, 2026 was 13.8%. For fiscal 2025 it was 11.4%, against -10.8% the year before. The highest annual figure on record is 11.4% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202511.4%+22.2
FY2024Dec 31, 2024-10.8%−1.5
FY2023Dec 31, 2023-9.3%−13.8
FY2022Dec 31, 20224.4%+410.8
FY2021Dec 31, 2021-406.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202619.0%+5.7
Q2 FY2026Jun 30, 202611.2%−1.7
Q1 FY2026Mar 31, 202613.7%+4.0
Q4 FY2025Dec 31, 20259.8%+25.5
Q3 FY2025Sep 30, 202513.3%+21.9
Q2 FY2025Jun 30, 202512.9%+13.0
Q1 FY2025Mar 31, 20259.6%+30.3
Q4 FY2024Dec 31, 2024-15.7%−15.8
Q3 FY2024Sep 30, 2024-8.6%+7.7
Q2 FY2024Jun 30, 2024-0.1%+4.3
Q1 FY2024Mar 31, 2024-20.7%+2.4
Q4 FY2023Dec 31, 20230.1%−9.7
Q3 FY2023Sep 30, 2023-16.3%−63.1
Q2 FY2023Jun 30, 2023-4.4%+67.4
Q1 FY2023Mar 31, 2023-23.2%+49.3
Q4 FY2022Dec 31, 20229.8%+202.5
Q3 FY2022Sep 30, 202246.8%+300.4
Q2 FY2022Jun 30, 2022-71.8%+454.6
Q1 FY2022Mar 31, 2022-72.4%–
Q4 FY2021Dec 31, 2021-192.8%–
Q3 FY2021Sep 30, 2021-253.6%–
Q2 FY2021Jun 30, 2021-526.4%–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?